Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectssyndromeclinically significantchronicthe investigator
  Phrases that lowered it: cancertumorsdlprostateupper limit
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 6.1% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 46 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 33 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 2.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 76.7% (lowers risk) · Drug's FDA history
• Maximum age: 40 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% NCT01993212 · started 2014 · scored riskier than 58% of active trials completed
• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% NCT01993225 · started 2014 · scored riskier than 57% of active trials completed
• Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder NCT01607658 · started 2012 · scored riskier than 59% of active trials completed
• Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems NCT01743235 · started 2012 · scored riskier than 5% of active trials completed
• Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function NCT03933618 · started 2015 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.